Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 3072586, 8 pages
http://dx.doi.org/10.1155/2016/3072586
Review Article

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

Immunogenicity Group, Department of Translational Medicine, Takeda Pharmaceutical USA, Inc., 35 Landsdowne Street, Cambridge, MA 02139, USA

Received 1 February 2016; Accepted 8 May 2016

Academic Editor: Shobha Purushothama

Copyright © 2016 Sam Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. N. Foltz, M. Karow, and S. M. Wasserman, “Evolution and emergence of therapeutic monoclonal antibodies what cardiologists need to know,” Circulation, vol. 127, no. 22, pp. 2222–2230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Shankar, C. Pendley, and K. E. Stein, “A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs,” Nature Biotechnology, vol. 25, no. 5, pp. 555–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Chirmule, V. Jawa, and B. Meibohm, “Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy,” The AAPS Journal, vol. 14, no. 2, pp. 296–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Hay, M. Recht, M. Carcao, and B. Reipert, “Current and future approaches to inhibitor management and aversion,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 2, pp. 15–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. G. Swann, M. Tolnay, S. Muthukkumar, M. A. Shapiro, B. L. Rellahan, and K. A. Clouse, “Considerations for the development of therapeutic monoclonal antibodies,” Current Opinion in Immunology, vol. 20, no. 4, pp. 493–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Thorpe and S. J. Swanson, “Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures,” Nephrology Dialysis Transplantation, vol. 20, no. 4, pp. 16–22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Y. K. Hwang and J. Foote, “Immunogenicity of engineered antibodies,” Methods, vol. 36, no. 1, pp. 3–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Ponce, L. Abad, L. Amaravadi et al., “Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies,” Regulatory Toxicology and Pharmacology, vol. 54, no. 2, pp. 164–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Wadhwaa, C. Birda, P. Dilgera, R. Gaines-Dasb, and R. Thorpea, “Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biological,” Journal of Immunological Methods, vol. 278, no. 1-2, pp. 1–17, 2003. View at Google Scholar
  10. K. E. Stein, “Immunogenicity: concepts/issues/concerns,” Developments in Biologicals, vol. 109, pp. 15–23, 2002. View at Google Scholar · View at Scopus
  11. F. Baert, M. Noman, S. Vermeire et al., “Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease,” The New England Journal of Medicine, vol. 348, no. 7, pp. 601–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. G. M. Bartelds, C. L. M. Krieckaert, M. T. Nurmohamed et al., “Development of antidrug antibodies against Adalimumab and association with disease activity and treatment failure during long-term follow-up,” The Journal of the American Medical Association, vol. 305, no. 14, pp. 1460–1468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. B. A. Baldo, “Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses,” OncoImmunology, vol. 2, no. 10, article e26333, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. K.-U. Eckardt and N. Casadevall, “Pure red-cell aplasia due to anti-erythropoietin antibodies,” Nephrology Dialysis Transplantation, vol. 18, no. 5, pp. 865–869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan et al., “Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products,” Journal of Immunological Methods, vol. 289, no. 1-2, pp. 1–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Shankar, V. Devanarayan, L. Amaravadi et al., “Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1267–1281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, Draft Guidance for Industry. Assay Development for Immunogenicity Testing of Therapeutic Proteins, 2009, http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
  18. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, “Guidance for industry, Immunogenicity assessment for therapeutic protein products,” 2014, http://www.fda.gov/downloads/%20drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
  19. European Medicines Agency, Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use, European Medicines Agency, London, UK, 2012.
  20. European Medicines Agency, “Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins (Draft),” 2015, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf.
  21. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, “Draft guidance for industry. Assay development and validation for immunogenicity testing of therapeutic proteins, Revision 1,” 2016, http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm192750.pdf.
  22. Y.-M. C. Wang, L. Fang, L. Zhou, J. Wang, and H.-Y. Ahn, “A survey of applications of biological products for drug interference of immunogenicity assays,” Pharmaceutical Research, vol. 29, no. 12, pp. 3384–3392, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. AbbVie: Humira Insert, 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125057s310lbl.pdf.
  24. A. Patton, M. C. Mullenix, S. J. Swanson, and E. Koren, “An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen,” Journal of Immunological Methods, vol. 304, no. 1-2, pp. 189–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. H. W. Smith, A. Butterfield, and D. Sun, “Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA,” Regulatory Toxicology and Pharmacology, vol. 49, no. 3, pp. 230–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Meso Scale Discovery, “Immunogenicity Assay from Meso Scale Discovery,” 2012, http://www.mesoscale.com/.
  27. Meso Scale Discovery, MSD Technology Platform, 2013, http://www.mesoscale.com.
  28. Gyros, “Automated immunoassays at nanoliter-scale,” 2016, http://www.gyros.com/why-gyros/technology/.
  29. Genalyte, “Detection of isotype and IgG subclass anti-adalimumab antibodies with a multiplex photonic ring immunoassay,” 2014, http://www.info@genalyte.com.
  30. M. H. Hart, H. de Vrieze, D. Wouters et al., “Differential effect of drug interference in immunogenicity assays,” Journal of Immunological Methods, vol. 372, no. 1-2, pp. 196–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Dai, A. Schantz, A. Clements-Egan, M. Cannon, and G. Shankar, “Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity,” AAPS Journal, vol. 16, no. 3, pp. 464–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Zou, “Overcome drug and soluble target interferences in immunogenicity sample analysis for antibody therapy,” in Proceedings of the IBC's 16th Annual Immunogenicity for Biotherapeutics, Reston, Va, USA, 2015.
  33. G. Shankar, S. Arkin, L. Cocea et al., “Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations,” The AAPS Journal, vol. 16, no. 4, pp. 658–673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Amaravadi, A. Song, H. Myler et al., “2015 White paper on recent issues in bioanalysis: focus on new technologies and biomarkers (part 3—LBA, biomarkers and immunogenicity),” Bioanalysis, vol. 7, no. 24, pp. 3107–3124, 2015. View at Publisher · View at Google Scholar
  35. A. Vennegoor, T. Rispens, E. M. M. Strijbis et al., “Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis,” Multiple Sclerosis Journal, vol. 19, no. 5, pp. 593–600, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. P. A. Calabresi, G. Giovannoni, C. Confavreux et al., “The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL,” Neurology, vol. 69, no. 14, pp. 1391–1403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Oliver, Ó. Fernández, T. Órpez et al., “Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months,” Multiple Sclerosis, vol. 17, no. 3, pp. 368–371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. P. S. Sørensen, P. E. Hyldgaard Jensen, A. Haghikia et al., “Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab,” Multiple Sclerosis Journal, vol. 17, no. 9, pp. 1074–1078, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. Biogen Idec and Élan, Tysabri Insert, 2013, http://www.fda.gov/safety/medwatch/safetyinformation/%20safety-relateddruglabelingchanges%20/ucm106674.htm.